rosiglitazone has been researched along with Choroid Neovascularization in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hangai, M; He, S; Hinton, DR; Hsueh, WA; Ishibashi, T; Kim, S; Law, RE; Murata, T; Ryan, SJ; Xi, XP | 1 |
1 other study(ies) available for rosiglitazone and Choroid Neovascularization
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.
Topics: Animals; Blotting, Western; Cell Division; Cell Movement; Choroid; Choroidal Neovascularization; Chromans; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Fluorescein Angiography; Humans; Injections; Laser Coagulation; Ligands; Lymphokines; Macaca fascicularis; Male; Pigment Epithelium of Eye; Rats; Rats, Inbred BN; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |